* clinically significant symptoms prior to ip injection. * confirmed to be covid-19 rt-pcr positive or to have made close contact with sars-cov-2 infected patient. * history of virologically-confirmed sars, mers, or covid-19. * history of congenital or acquired immunodeficiency or autoimmune diseases. * positive result of hepatitis b, c, rpr test, or hiv. * history of disorder that inhibits intramuscular injection of the vaccine. * history of hypersensitivity and severe allergic reaction to any of the components of ip. * history of malignant tumor within 5 years prior to the first ip injection. * clinically significant chronic diseases that could cause safety concerns regarding covid-19. * scheduled of , or history of surgery under general anaesthesia prior to first ip injection, * female participant that is pregnant or is currently breastfeeding. * smoker or history of smoking within 12 weeks prior to first ip injection. * previous vaccination or treatment for prevention of covid-19. * vaccination prior to the first ip injection or scheduled of vaccination after second ip injection. * treated with immunoglobulin and/or blood/blood components prior to first ip injection. * chronic use of immunosuppressant prior to first ip injection. * participated in other clinical study prior to first ip injection, or scheduled to participate in other study during the study period. * healthcare worker or emergency response personnel. * conditions that may influence the evaluation of the study objectives.

* clinically significant symptoms prior to ip injection. * confirmed to be covid-19 rt-pcr positive or to have made close contact with sars-cov-2 infected patient. * history of virologically-confirmed sars, mers, or covid-19. * history of congenital or acquired immunodeficiency or autoimmune diseases. * positive result of hepatitis b, c, rpr test, or hiv. * history of disorder that inhibits intramuscular injection of the vaccine. * history of hypersensitivity and severe allergic reaction to any of the components of ip. * history of malignant tumor within 5 years prior to the first ip injection. * clinically significant chronic diseases that could cause safety concerns regarding covid-19. * scheduled of , or history of surgery under general anaesthesia prior to first ip injection, * female participant that is pregnant or is currently breastfeeding. * smoker or history of smoking within 12 weeks prior to first ip injection. * previous vaccination or treatment for prevention of covid-19. * vaccination prior to the first ip injection or scheduled of vaccination after second ip injection. * treated with immunoglobulin and/or blood/blood components prior to first ip injection. * chronic use of immunosuppressant prior to first ip injection. * participated in other clinical study prior to first ip injection, or scheduled to participate in other study during the study period. * healthcare worker or emergency response personnel. * conditions that may influence the evaluation of the study objectives.

- clinically significant symptoms prior to ip injection. - confirmed to be covid-19 rt-pcr positive or to have made close contact with sars-cov-2 infected patient. - history of virologically-confirmed sars, mers, or covid-19. - history of congenital or acquired immunodeficiency or autoimmune diseases. - positive result of hepatitis b, c, rpr test, or hiv. - history of disorder that inhibits intramuscular injection of the vaccine. - history of hypersensitivity and severe allergic reaction to any of the components of ip. - history of malignant tumor within 5 years prior to the first ip injection. - clinically significant chronic diseases that could cause safety concerns regarding covid-19. - scheduled of , or history of surgery under general anaesthesia prior to first ip injection, - female participant that is pregnant or is currently breastfeeding. - smoker or history of smoking within 12 weeks prior to first ip injection. - previous vaccination or treatment for prevention of covid-19. - vaccination prior to the first ip injection or scheduled of vaccination after second ip injection. - treated with immunoglobulin and/or blood/blood components prior to first ip injection. - chronic use of immunosuppressant prior to first ip injection. - participated in other clinical study prior to first ip injection, or scheduled to participate in other study during the study period. - healthcare worker or emergency response personnel. - conditions that may influence the evaluation of the study objectives.

- clinically significant symptoms prior to ip injection. - confirmed to be covid-19 rt-pcr positive or to have made close contact with sars-cov-2 infected patient. - history of virologically-confirmed sars, mers, or covid-19. - history of congenital or acquired immunodeficiency or autoimmune diseases. - positive result of hepatitis b, c, rpr test, or hiv. - history of disorder that inhibits intramuscular injection of the vaccine. - history of hypersensitivity and severe allergic reaction to any of the components of ip. - history of malignant tumor within 5 years prior to the first ip injection. - clinically significant chronic diseases that could cause safety concerns regarding covid-19. - scheduled of , or history of surgery under general anaesthesia prior to first ip injection, - female participant that is pregnant or is currently breastfeeding. - smoker or history of smoking within 12 weeks prior to first ip injection. - previous vaccination or treatment for prevention of covid-19. - vaccination prior to the first ip injection or scheduled of vaccination after second ip injection. - treated with immunoglobulin and/or blood/blood components prior to first ip injection. - chronic use of immunosuppressant prior to first ip injection. - participated in other clinical study prior to first ip injection, or scheduled to participate in other study during the study period. - healthcare worker or emergency response personnel. - conditions that may influence the evaluation of the study objectives.